Synergy CHC Corp. Enters \$36 Million Equity Purchase Agreement with Hudson Global Ventures
Key Highlights for Investors
- Equity Purchase Agreement Signed: Synergy CHC Corp. (“the Company”) has entered into a significant equity purchase agreement with Hudson Global Ventures, LLC (“the Investor”).
- Up to \$36 Million in Common Stock: The agreement gives Synergy CHC Corp. the right (but not the obligation) to direct Hudson Global Ventures to purchase up to \$36 million worth of the Company’s common stock, par value \$0.00001 per share, subject to certain terms and conditions.
- Purchase Flexibility and Conditions: The Company may request, via “Put Notices,” that the Investor purchase shares in minimum increments of \$25,000 and up to a maximum of \$2.5 million per “Put,” or 200% of the average daily trading value, whichever is less. The aggregate amount cannot exceed \$36 million.
- Shareholder Approval Requirement & Exchange Cap: The agreement contains a shareholder approval trigger under Nasdaq Rule 5635(d), which caps issuances at 2,978,486 shares unless approved by shareholders. Any issuance above this cap requires shareholder approval, which is critical for investors monitoring dilution risk.
- Purchase Price Mechanisms:
- The initial purchase price per share is set at 95% of the average of the three lowest traded prices of the Company’s common stock on Nasdaq during the five trading days prior to the Put Date.
- The final purchase price for each Put is set at the lesser of the initial purchase price or 95% of the lowest closing price during the three trading days following the date the Investor receives the Put Shares.
- Warrant Issuance: As part of this transaction, the Company will issue a warrant to Hudson Global Ventures to purchase 1,540,000 shares of common stock (subject to adjustment for stock splits, dividends, etc.).
- Registration Rights: The Company is required to file a registration statement covering the resale of shares issued under the agreement, including those issuable upon exercise of the warrant, within 30 days and to keep it effective until all shares have been sold.
- Investor Ownership Cap: The Investor is restricted from beneficially owning more than 4.99% of the outstanding common stock immediately after any purchase, which could limit the pace of investment and provide some anti-takeover protection.
- Price Protection for Investors: No shares may be issued to the Investor if the lowest traded price of the common stock over the ten trading days prior to a Put Date falls below \$0.01, and the shares must not be classified as “penny stock” under SEC rules at the time of issuance.
- Legal and Administrative Fees: The Company will pay \$20,000 to the Investor’s legal counsel for expenses relating to agreement preparation and cover all Transfer Agent fees related to the transaction.
- Ongoing Compliance: The Company must remain listed and in good standing on Nasdaq (the “Principal Market”) and in compliance with all applicable SEC and listing requirements to continue utilizing the equity line.
What Shareholders Need to Know
- Potential for Significant Dilution: If the full \$36 million is drawn and shares are issued at prevailing market prices, existing shareholders could see substantial dilution, especially if the stock price is low when Puts are made. The Exchange Cap and shareholder approval requirements are designed to provide some dilution control, but the risk remains if approval is obtained.
- Flexible Corporate Financing: This equity line offers Synergy CHC Corp. a flexible mechanism to raise capital on an as-needed basis, which can support growth initiatives, acquisitions, or strengthen the balance sheet. However, it also means additional shares could enter the market at potentially discounted prices, putting pressure on the stock.
- Short Sale Restrictions: The Investor is prohibited from engaging in short sales of the Company’s stock during the agreement period, which may help reduce downward volatility associated with such trades.
- Price Sensitive Information:
- The agreement and related filings—including any material definitive agreements, share issuances, or registration statements—are likely to be material events for investors and the market.
- Any failure to obtain shareholder approval for issuances above the Exchange Cap, or any breach of Nasdaq or SEC requirements, could result in the suspension of the agreement and have a negative impact on liquidity and share value.
- As part of its disclosure obligations, Synergy CHC Corp. will publicly file all material terms and agreements via Form 8-K and other SEC filings, ensuring that investors receive timely updates on developments.
- Warrant Exercise and Adjustments: The warrant issued to Hudson Global Ventures is subject to adjustment for stock splits, dividends, and similar transactions. This means the actual number of shares, and the exercise price, could change in the event of corporate actions—another consideration for potential dilution.
- Investor Status and Restrictions: Hudson Global Ventures is not an affiliate, officer, or director of Synergy CHC Corp., and the Company has represented that the Investor is not acting as a broker-dealer or underwriter in this transaction.
Conclusion
The \$36 million equity purchase agreement with Hudson Global Ventures provides Synergy CHC Corp. with a potentially significant source of capital, subject to market conditions, continued listing compliance, and shareholder approvals. While this capital can support the Company’s strategic initiatives, it also introduces the risk of dilution for existing shareholders if drawn down at lower share prices. The automatic registration of resale shares, investor ownership limits, and short sale restrictions are intended to balance the interests of the Company and its shareholders.
Investors should closely monitor future SEC filings, shareholder meetings regarding approval, and any Put Notices delivered under this agreement, as these could have direct and material impacts on share value and ownership structure.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The information provided is based on public filings and agreements and may be subject to change or clarification in future disclosures.
